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Remarkable and continued growth in the field of brain
aging research has been fueled by a confluence of fac-
tors. Developments in molecular biology, imaging, and
genetics coupled with the imperative caused by the
aging of the population has created fertile ground for
improved understanding of the interaction between
brain function and behavior. Aging changes in neuro-
chemical systems may account for the spectrum of cog-
nitive and behavioral states of successfully aged per-
sons, but may also contribute to enhanced vulnerability
to depressive or dementing illness. In particular, the
refinement of in vivo imaging approaches to investi-
gating the structure and function of the aging brain
has provided the opportunity to strengthen our knowl-
edge of the biological substrate of the aging brain and
neuropsychiatric disorders, and translate these into
therapeutics.
an (and woman) has long been fascinated with
the workings of the human mind.Yet it is only recently
that we have developed the tools to explore its biologi-
cal underpinnings in the living state.The 1990 to 2000
interval was hailed as the Decade of the Brain.Advances
in imaging, genetics, molecular biology, and pharmacol-
ogy continue to advance our horizons in neuroscience
research, but the scientific yield from these highly pro-
ductive past 10 years will surely both usher in the devel-
opments of the future and guide the  research achieve-
ments to important clinical applications. The gap
between bench and bedside is narrower than ever and,
importantly,there is increasing focus on not only length-
ening the life span, but also improving the quality of
mental and physical health in aging.
Anatomical and neurochemical systems
affected by brain aging
Imaging structural brain changes in aging
Structural brain changes accompanying normal aging
and neurodegenerative and psychiatric disorders may
parallel and provide insight into the etiology of changes
in cognition, mood, and motor function in the elderly.
However,postmortem studies of brain morphology are
plagued by artifacts caused by changes in hydration
states just prior to death and tissue fixation.These stud-
ies are biased toward end-stage disease states and per-
mit only retrospective correlations with measures of
brain function and behavior.Magnetic resonance imag-
ing (MRI) offers a means of assessing structural brain
changes in vivo and provides the opportunity to evalu-
ate the relationship of morphologic parameters to
mood, neuropsychological dysfunction, and treatment
response.
It is well known from both imaging and autopsy series
that cerebrospinal fluid (CSF) increases and cerebral
volume reductions accompany normal human aging.
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Basic researchSeveral studies have suggested that age-related volume
loss tends to affect some brain regions more than others.
Jernigan et al
1 localized aging changes in brain volume
to be most marked in the caudate nucleus,anterior dien-
cephalic structures,association cortices,and mesial tem-
poral structures,with no changes found in the thalamus
and anterior cingulate cortex. Murphy et al
6 also found
significantly larger MRI-determined volume losses in
the caudate and lentiform nuclei than in the cerebral
hemispheres in normal elderly men.These authors spec-
ulated that this finding was in accord with motor abnor-
malities encountered in the elderly. Similarly, preferen-
tial reductions in the size of the hippocampal formation
in normal aging have been shown to correlate with
delayed memory performance.
9 It is important to bear
in mind that age-related cerebral volume loss is highly
variable among individuals and further accelerated by
coincident medical illness. Conversely, DeCarli et al
10
showed that temporal lobe volumes did not change over
a range of 19 to 92 years of age, when only successfully
aged men were included.
Due to considerable intersubject variability of age-relat-
ed structural brain changes,cross-sectional study designs
provide limited information about the rates and influ-
ences on such alterations.In a unique effort to determine
the annual rate of brain volume changes in the healthy
elderly, the Baltimore Longitudinal Study of Normal
Aging has followed 94 elders with five annual MRI
assessments. Preliminary findings support substantial
annual intrasubject whole-brain volume reductions esti-
mated to average 5.5 mL, with 1.4 mL increases in total
CSF volume.
11
Nonspecific foci of increased white matter signal may be
observed by MRI in normal individuals of all ages, but
clearly increase in frequency with age,particularly after
age 60.
7,12,13 Although of uncertain clinical significance,
these white matter hyperintensities have been found to
be especially prevalent in persons with prominent risk
factors for cerebrovascular disease, particularly hyper-
tension.
13-15 Pathologic correlates also point to an
ischemic basis for these lesions,
16,17 and blood flow reduc-
tions have been reported in association with white mat-
ter hyperintensities.
18-21Yet,whether white matter hyper-
intensities are associated with diminished cognitive
function in aging is still unsettled.
14,17,22
Although substantial improvements in image processing
and quantitative methods have recently been made,there
are conflicting results among the numerous structural
MRI studies of the aging brain due to a number of fac-
tors.These include methodological differences in imaging
data acquisition and analysis,small sample size,and selec-
tion bias, such as failure to control for cerebrovascular
risk factors. Still, morphologic changes in the brain that
accompany aging follow processes—often with substan-
tial delay—that begin at the cellular level.For this reason,
investigative techniques that reflect functional or physio-
logic brain changes are typically more sensitive approach-
es for identifying the earliest and potentially reversible
changes of healthy or pathologic aging.
Cell loss in normal aging
It was widely accepted that substantial neuronal loss
occurred during normal aging with values as high as 50%
in some hippocampal subregions, and that this was like-
ly to be responsible for age-related decline in memory.
Most early neuropathological studies used measures of
neuronal density rather than cell number as the basis for
measurement of cell loss.However,with the more recent
application of stereological techniques to this field,it has
become clear that normal aging is not accompanied by
significant global decline in neuronal number.
23,24Within
the hippocampus and associated cortical regions,there is
no significant cell loss in entorhinal cortex,CA1,or tem-
poral cortex of the undemented elderly.
25 Some age-
related cell loss does occur in the dentate gyrus and
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Selected abbreviations and acronyms
AChE-I acetylcholinesterase inhibitor
AD Alzheimer’s disease
APP amyloid precursor protein
CBF cerebral blood flow
CBV cerebral blood volume 
ChAT choline acetyltransferase
CMRglc cerebral metabolic rate of glucose utilization
CMRO2 cerebral metabolic rate of oxygen
CSF cerebrospinal fluid
GABA γ -aminobutyric acid
HRT hormone replacement therapy
5-HT 5-hydroxytryptamine
MRI magnetic resonance imaging
NMDA N-methyl-D-aspartate
PET positron emission tomography
SPECT single-photon emission computed tomography169
subiculum. It is, therefore, not possible to account for
memory deficits in the elderly in terms of cell loss alone.
The substrate for such change is more likely to be relat-
ed to disruption of important hippocampal circuits short
of cell loss.Such changes include the presence of neuro-
fibrillary tangles within the entorhinal cortex,
25 synapse
loss in the terminal zone of the perforant pathway of the
dentate gyrus,
26 changes to dendrites,disruption of long-
term potentiation,
27 and decreases in the expression of
the N-methyl-D-aspartate (NMDA) receptor in the mol-
ecular layer of the dentate gyrus.
24
Age-related alterations in brain metabolism 
and perfusion 
Functional imaging tools, such as positron emission
tomography (PET),single-photon emission tomography
(SPECT),
133Xe- or xenon-enhanced computed tomogra-
phy (CT), and optical imaging have permitted in vivo
evaluation of brain perfusion and metabolic measure-
ments.Yet, whether generalized physiologic measures
such as resting cerebral blood flow (CBF) are altered in
normal aging remains a point of controversy. Using the
133Xe inhalation method, which suffers from particularly
poor spatial resolution relative to other methods, sever-
al investigators have demonstrated a significant reduc-
tion in mean CBF throughout the adult life span.
28-31With
PET,Leenders et al
32 similarly demonstrated a decline of
0.5%/year in CBF, cerebral blood volume (CBV), and
cerebral metabolic rate of oxygen (CMRO2) in cortical
brain regions. Several other investigators have also
observed aging declines in CMRO2, with a milder influ-
ence of age on CBF and oxygen extraction.
33-36 One
important potential confound in many of these studies is
the diluting influence of age-related cerebral volume loss
on these measurements.Due to the limited spatial reso-
lution of many functional imaging techniques,partial vol-
ume averaging of cortical signal with enlarged sulcal CSF
spaces can result in underestimation of metabolic para-
meters in older subjects.
37 Applying MRI-based partial
volume correction to [
15O]water PET data,Meltzer et al
38
recently demonstrated no reduction in cortical CBF in
healthy aging.This work challenges the interpretation of
older studies, which did not account for this source of
artifact that may dilute metabolic measures in the elder-
ly.
39 Although resting CBF may be normal in the suc-
cessfully aged individual, age effects on small arterioles
may reduce the autoregulatory capacity of the cere-
brovascular system to respond to vasodilatory chal-
lenge,
40 thus diminishing the brain’s ability to compen-
sate for changes in systemic perfusion pressure and per-
haps enhancing its susceptibility to ischemic damage.
PET studies of brain glucose utilization have similarly
demonstrated disagreement among reports as to
whether brain function declines with age. In 1982, Kuhl
et al
41 reported a gradual aging decline in the mean cere-
bral metabolic rate of glucose utilization (CMRglc).
Later studies supported a regional preference for age-
related reductions in brain glucose metabolism in the
frontal lobes, which were most marked after age 60.
42,43
Duara et al,
44 however, found no relationship between
age and regional CMRglc in healthy men. Large inter-
subject variability in the neurobiologic effects of aging
has been noted by several investigators.
44,45 These
reports, individually limited by small sample sizes, sug-
gest that aging effects on brain function are likely high-
ly variable,affected by structural brain changes and sys-
temic factors,and may differ between “successful aging”
and individuals with substantial medical burden.
Alterations in neurotransmitter systems
The functional integrity of several neurotransmitter sys-
tems is altered by the aging process. Characterizing the
profile of normal aging changes in neurotransmitter-
mediated synaptic processes is the foundation upon
which we will come to decipher the biological basis of
behavioral and mood alterations accompanying aging.
Further, the potential interaction between age effects
and neurochemical disturbances associated with neuro-
psychiatric disease states may influence the susceptibili-
ty of the elderly to certain neurobehavioral disorders.
Our knowledge of the effect of age on neuroreceptor
function is primarily inferred by postmortem studies,with
limited and variable regional sampling of the brain, and
by animal models,which may not appropriately represent
human brain aging.In contrast to studies of pathological
changes in aging, there are many problems associated
with the biochemical study of neurotransmission in
humans.These include the effects of postmortem delay,
hypoxia, and drug treatment, as well as the fundamental
point that the material is removed most often removed
following a terminal illness, which may itself influence
neurotransmission regardless of the age at which the
patient died.The reader is referred to a comprehensive
review of the subject by DeKosky and Palmer.
46
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for neuroreceptors,transporters,and other markers of
neuronal function, it is possible to study the effects of
aging and disease on brain neurotransmitter systems in
vivo with PET. This approach permits whole-brain
quantitative imaging in well-characterized subjects,
with the potential for obtaining longitudinal measures.
Such work has demonstrated specific aging reductions
in dopamine and serotonin (5-hydroxytryptamine 
[5-HT]) receptor subtypes (Figure 1).
47-50 Interestingly,
there is evidence that some neuroreceptors actually
increase in density with age, a finding of note in the
opiate system.
51 PET techniques are desirable relative
to neuroendocrine challenge studies,which lack spatial
localizing information and physiologic specificity.
However,the combination of PET with neuropharma-
cologic probes is a powerful technique for localizing
and quantifying neurotransmitter-mediated function in
aging and disease.
Cholinergic system
There is considerable evidence for a presynaptic cholin-
ergic deficit during aging in many brain regions based
on reductions in the enzyme responsible for the synthe-
sis of acetylcholine,choline acetyltransferase (ChAT),in
cortex and striatum (as reviewed Palmer and
DeKosky
52) and in acetylcholine synthesis in temporal
cortex.
53 Furthermore, there are decreases with age in
both muscarinic and nicotinic cholinergic receptors.
54
Using proton magnetic spectroscopy, Cohen et al
55
demonstrated reductions in the uptake of circulating
choline with advancing age. Selective imaging ligands
for the cholinergic system have proved elusive.Howev-
er,PET studies with the relatively nonselective cholin-
ergic receptor ligands [
11C]benztropine, [
11C]tropanyl
benzilate, and [
11C]-N-methylpiperidyl benzilate
(NMPB) have supported in vivo losses in muscarinic
receptor density with age,although they disagree on the
magnitude of the reductions.
56-58Also,modest reductions
in cholinergic terminal density with aging have been
demonstrated by SPECT imaging of the vesicular
acetylcholine transporter [
123I]iodobenzovesamicol.
59
Monoaminergic systems
There is wide variation in the response of monoaminer-
gic systems to aging.While postmortem studies show
considerable loss of markers of the 5-HT system (5-HT,
5-HT1A,and 5-HT2A receptors),particularly in the neo-
cortex,and of dopaminergic markers (dopamine,major
metabolites,transporter,and receptors) in the striatum,
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Basic research
Figure 1. [
18F]Altanserin positron emission tomography (PET) imaging of the 5-hydroxytryptamine (serotonin) type-2A receptor (5-HT2A). Left.
[
18F]Altanserin PET images (summed over 20 to 90 min postinjection and displayed with scale normalized to cerebellum) at three brain levels
in healthy subjects, aged 20 (left) and 66 (right). Right. Scatter plot demonstrates a linear decline in the binding of [
18F]altanserin to 5-HT2A
receptors in the lateral orbitofrontal cortex over the adult life span.
Young normal Elderly normal171
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there is little evidence of change outside those regions
or in markers of the noradrenergic system.
52 The devel-
opment of selective imaging ligands for the 5-HT and
dopamine binding sites has allowed these systems to be
further studied in humans in vivo.
PET studies confirm substantial aging reductions in spe-
cific binding to dopamine D1 and D2 receptors.
47,48,60
Further, alterations in cognition and coordination of
motor activity that frequently accompany aging have
been shown to correlate with PET measures of
dopamine receptor function.
61Aging losses of presynap-
tic dopamine transporter sites have also been demon-
strated with PET and SPECT,suggesting that age affects
the integrity of dopaminergic neuronal pathways.
62-65
Recently developed PET ligands for several 5-HT
receptor subtypes and the 5-HT transporter have facili-
tated in vivo imaging of this important neurotransmitter
system,which is central to mood and sleep regulation.
66,67
Marked widespread aging reductions in binding of the
pharmacologically well-characterized 5-HT2A receptor
using [
18F]altanserin and [
18F]setoperone have been
shown by several investigators.
49,50,68 The magnitude of
the inverse relationship between age and 5-HT2A recep-
tor binding supports the hypothesis that loss of seroton-
ergic function in aging may contribute to the suscepti-
bility of the elderly to alterations in mood and
5-HT–mediated behaviors. Intriguing preliminary evi-
dence suggests gender differences in the effect of age on
the 5-HT1A receptor.
69
Amino acid systems
Glutamic acid decarboxylase, responsible for the syn-
thesis of γ -vinyl γ -aminobutyric acid (GABA), declines
with age in cortex, hippocampus, and striatum, while
there is limited evidence for decreases in markers of the
glutamatergic system (transporter and NMDA recep-
tor).
46,70 It is,however,difficult to assess the status of the
presynaptic glutamatergic system since the neurotrans-
mitter is a ubiquitous component of all cells.
71
While no changes have been reported in [
3H]MK801
binding (to the ion channel) from middle age to old age,
age-related changes in the ability of glutamate and
glycine binding sites to influence binding within the
channel have been observed.
72,73 For example, the abili-
ty of glutamate and glycine to enhance [
3H]MK801
binding in the frontal cortex is reduced from a 44%
increase in young adults to a 35% increase in 80- to 100-
year-old humans.
74 Furthermore, spermine stimulation
of [
3H]MK801 binding via the polyamine site disappears
by 80 years of age and zinc inhibition also declines with
increased age.
74 Reduction in binding to one or more
sites on the NMDA receptor complex with age may
reflect losses of the entire receptor complex,a selective
loss of certain subunits,or both.There is some evidence
from studies in mice that changes in receptor subunit
composition occur with age and may form the basis for
changes in the affinity of certain binding sites.
75
Influence of gender on brain aging
The profound impact of sex steroids on brain structure
and function is evidenced by sexual dimorphisms in
brain organization and development,
76 which have been
associated with gender-based differences in behavior
and learning.
77 Recent evidence of male–female differ-
ences in brain aging supports an ongoing dynamic rela-
tionship between sex steroids and neural structure and
function.This includes work by Honeycutt et al,
78 which
demonstrates differential aging patterns for the mor-
phology of mesial temporal structures, particularly the
amygdala, in men and women. In vivo evidence of
male–female differences in neuroreceptor distribution
has been shown for 5-HT2A receptors, and a specific
age–gender interaction on 5-HT1A receptors has recent-
ly been reported.
69 Gender preferences for psychiatric
disorders, particularly depressive illness, also support a
biological underpinning for functional brain differences
in men and women.Women clearly exhibit higher rates
of depression in early and middle adulthood, with
enhanced risk associated with surgical menopause and
antiestrogen treatment for breast cancer.
79,80 However,
there is evidence for a narrowing of the gender gap in
mood disorders in older middle adulthood, for which a
neuroendocrine basis is speculated.
81,82
Animal models demonstrating a positive effect of estro-
gen on memory task performance,particularly working
memory,
83,84 and the observation that normal hormonal
cycling affects cognitive performance in women
85-88 sug-
gest a role for ovarian steroids in mediating cognitive
function. However, variable outcomes have resulted
from clinical investigations of hormone replacement
therapy (HRT) and cognition in aging women.In a com-
munity-based study of over 700 postmenopausal
women, Jacobs and colleagues
89 noted higher cognitive
measures in HRT users relative to nonusers.They alsofound slight improvements in verbal memory perfor-
mance over the follow-up interval.However,these find-
ings were not independent of age and education level.
Other investigators have reported no clear beneficial
effect of estrogen replacement therapy on cognitive
function,
90,91 and no relationship between endogenous
estrogen levels on cognitive test performance.
92,93 (Inter-
estingly, an association between higher endogenous
testosterone levels and cognitive performance has been
noted in women.
92) It has been further suggested that a
lack of epidemiological evidence of gender differences
in cognitive decline with aging argues against a link
between estrogen deficiency and cognitive dysfunction.
94
Research to date on male aging has been limited and the
clinical relevance of the aging decline of testosterone
levels in men is debated.
95 Although androgens clearly
play a role in brain development and sexual brain
dimorphisms, central mechanisms for modulating
human behavior are less well characterized (for a
review,see reference 96).Androgen receptors are found
in many brain regions with particular localization to the
hippocampus,
97 where, similar to estrogen, they modu-
late hyperpolarization of pyramidal cells in the CA1
region.
98 In healthy young men,testosterone levels have
been shown to correlate positively with spatial cognitive
function and negatively with verbal performance.
99 Ben-
eficial effects on spatial cognitive function in men have
been associated with an optimal level of testosterone,
with deterioration of performance observed at both
high and low levels.
100 Although the concept of testos-
terone supplementation remains controversial,random-
ized,controlled trials of androgen replacement therapy
in healthy older men have demonstrated enhanced spa-
tial cognitive ability.
101 Overall,the potential benefits of
androgen replacement in elderly men appear to weigh
favorably against minor potential added risks to cardio-
vascular and prostate health.
102
Late-life neuropsychiatric disorders
Depression
The association of evidence of disruption of structural
brain integrity (eg, white matter lesions) and late-life,
particularly late-onset, depression further underscores
the potential multiplicity of biological factors relevant to
depressive illness occurring in the elderly.
103-105The corre-
lation between white matter hyperintensities and hyper-
tension and/or atherosclerotic disease may parallel and
provide insight into the role of cerebral ischemia in the
etiology of late-life depression,since an increased preva-
lence of both cerebrovascular risk factors
103 and white
matter hyperintensities has been observed in elderly
depressed patients,
106 particularly those with a late onset
of their disease.
22,104,107,108 These observations have led
some investigators to postulate an MRI-defined vascu-
lar or atherosclerotic form of depression,
107,109 which sup-
ports a strong link between aging and biological factors
in depression occurring in the elderly.Also,evidence for
serotonergic control of the regulation of CBF
110,111 and
the potential influence of age on this regulatory mecha-
nism
112 suggest an interaction—although as yet ill-
defined—between disturbances in serotonergic function
and risk of cerebral ischemic injury.
Depression has been widely attributed to deficient 5-
HT neurotransmission.In the unique setting of geriatric
depression, age-related alterations in the 5-HT system
may perturb its functional integrity and thus potential-
ly contribute to the high prevalence and distinct char-
acter of depression in late life.Postmortem studies have
reported conflicting findings of 5-HT receptor status in
suicide victims.
113-119 In a small group of elderly nonsui-
cide depressed patients, reductions in binding to 5-
HT2A,but not to 5-HT1A,sites in temporal,frontal,and
parietal cortex were reported using membranes.
120
Using autoradiographic techniques, the density (Bmax)
for the 5-HT1A receptor was reduced by approximate-
ly 40% in the superficial layers of frontal cortex (Brod-
mann area 9) from patients undergoing surgery for
intractable depression.
71 It is also worth noting that
there was a 30% to 40% reduction in the concentration
of the 5-HT metabolite, 5-hydroxyindoleacetic acid (5-
HIAA), in the ventricular CSF of these depressed
patients,underlining the possible relationship between
disturbances of serotonergic neurotransmission and
depressive symptoms.
Evaluation of serotonergic function through imaging tech-
niques has offered a unique approach to evaluating the
heterogeneity of depression in the elderly. In an attempt
to assign neurochemical specificity to the blood flow and
metabolic disturbances reported in depression,
121-123 fluo-
rodeoxyglucose (FDG) PET coupled with the 5-HT–
releasing agent dl-fenfluramine provided indirect yet in
vivo evidence of serotonergic dysfunction in the prefrontal
cortex in depressed patients, who exhibited a blunted
response relative to healthy controls.
124,125 With the subse-
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172quent development of selective imaging agents for sero-
tonergic receptor sites,it became possible to quantify cen-
tral 5-HT binding in depressed patients. Of particular
interest are the 5-HT2A and 5-HT1A receptors and the 
5-HT transporter, which are all heavily implicated in the
antidepressant response (Figure 2).There are few pub-
lished studies to date of serotonergic PET imaging in
mood disorders and fewer conducted in elderly patients.
Biver et al
126 demonstrated a significant reduction in the
binding of [
18F]altanserin to right orbitofrontal 5-HT2A
receptors in a group of mid-life depressed subjects.How-
ever,this agent failed to show a change in 5-HT2A recep-
tor binding in late-life depression.
127 Drevets et al
128
recently reported reductions in 5-HT1A binding of
[
11C]WAY100635 to mesiotemporal and brainstem raphe
areas in familial mood disorders including bipolar depres-
sives.Whether this finding is generalizable to nonfamilial
forms of mood disorders and late-life depression is yet
uncertain.The capability to selectively evaluate neuro-
transmitter binding sites in vivo will likely continue to be
a valuable tool for determining the biological underpin-
nings of late-life depression and sources of treatment
response variability among patients.
Alzheimer’s disease: breaking 
the disease barrier 
Alzheimer’s disease (AD), the most common form of
dementia,has enormous and growing public health sig-
nificance. A disease of aging, the financial and 
social burdens of AD are compounded by recent and
continued increases in the average life span.
129,130
It has been estimated that the prevalence of AD will
continue to climb at a rapid rate,with an expected qua-
drupling of cases in the United States over the next 50
years.
130 Thus, the need for developing early diagnostic
markers to complement new therapeutic approaches is
more acute than ever before. Indeed, a modest goal of
instituting treatment that could delay disease onset by
just 2 years would profoundly impact these projections,
resulting in 2 million fewer cases by 2050.
Biological basis of Alzheimer’s disease
Cell death and histopathological changes affecting a
number of neuronal systems are considered to result in
the development of the typical symptomatology of AD
characterized by gross and progressive impairments of
cognitive function.The histopathological features are
intracellular neurofibrillary tangles formed from a
hyperphosphorylated form of the microtubule-associat-
ed protein, tau, and extracellular deposits of a 40/42
amino acid peptide,Aβ (derived from amyloid precursor
protein [APP]), often in the form of senile or neuritic
plaques. Plaques, tangles, and cell loss have a character-
istic regional and temporal distribution in the AD brain,
affecting entorhinal,hippocampal,and temporal cortical
structures first and frontal and parietal cortices later in
the disease process, while sparing primary sensory and
primary motor areas.
131 Indeed, this pathology is reflect-
ed in the characteristic regional pattern of blood flow
and metabolic disturbances demonstrated by PET or
SPECT imaging in early AD. Evidence from biochemi-
cal studies also indicates that certain subcortical stuc-
tures, including the nucleus basalis of Meynert and the
dorsal raphe are also affected early in the disease.
132
Most cases of AD are considered to be sporadic and
therefore of unknown cause;however,there are a num-
ber of autosomal dominant mutations (Table I) that
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Figure 2. Combined structural and functional imaging. The sagittal brain
image (left) illustrates the distribution of 5-HT transporter bind-
ing sites imaged with positron emission tomography (PET) and
[
11C](+)-McN5652 (summed over 40 to 90 min postinjection).
High-resolution T1-weighted magnetic resonance imaging (MRI)
(middle) provides detailed anatomic information. However, the
coregistration of the PET and MRI depicted in the overlay image
(right) offers a unique combination of structural and functional
data. The localization of the raphe nuclei, which are not visible
by MRI alone, are functionally and anatomically defined by the
coregistered images.
Chromosome Gene Number of Age of Proportion
mutations onset (years) cases
21 APP 9 50s <0.5%
14 PSI >40 40s 2%-4%
1 PS2 2 50s <0.5%
Table I. Genes causing Alzheimer’s disease (AD).cause AD and several genetic risk factors, the best
known of which is apolipoprotein E (apo E) ε 4 poly-
morphism, the presence of which carries an approxi-
mately sixfold greater risk of developing AD.
133 While
the disease-causing mechanism behind apo E remains
controversial,most studies indicate that mutations in the
genes APP, presenilin 1 (PS1), and presenilin 2 (PS2)
alter the metabolism of APP so as to favor production
of a long form of Aβ (Aβ 1-42) (see,for example,refer-
ence 134).
Neurotransmitter changes in Alzheimer’s disease
The majority of biochemical studies of AD have relied
on information derived from postmortem brain, which
typically represents the late stage of the disease (8-10
years after onset of symptoms).In these studies,there is
considerable evidence for multiple neurotransmitter
abnormalities affecting many brain regions. However,
investigations of biopsy tissue taken from AD patients
3 to 5 years (on average) after the onset of symptoms
indicate that a selective neurotransmitter pathology
occurs early in the course of the disease.
132
Acetylcholine. Changes affecting many aspects of the
cholinergic system in patients with AD have been
reported since the initial discovery of deficits in ChAT
activity in postmortem brains.
135-137 In biopsy samples
from AD patients,presynaptic markers of the choliner-
gic system were also uniformly reduced.
132 Thus, ChAT
activity, choline uptake, and acetylcholine synthesis are
all reduced to between 30% and 60% of control values.
The clinical correlate of this cholinergic deficit in AD
was until recently considered to be cognitive dysfunc-
tion. Such a conclusion was supported by clinicopatho-
logical studies in AD and parallel experiments in non-
human primates or rodents, which demonstrated
disruptive effects of basal forebrain cholinergic lesions
on cognitive functions.Furthermore,cholinergic deficits
in AD occur to the greatest extent in cortical areas pri-
marily concerned with memory and cognition: the hip-
pocampus,adjacent temporal lobe regions,and selected
frontal areas. Such studies led to the “cholinergic
hypothesis of geriatric memory dysfunction.”
138
On the basis of the above evidence, neocortical cholin-
ergic innervation appears to be lost at an early stage of
the disease and this is supported by a recent study where
the cholinergic deficit (reduced ChAT activity) has been
related to Braak staging.
131 Braak stages I and II are con-
sidered to represent the earliest presentation of AD
with neurofibrillary tangles in entorhinal cortex, and a
20% to 30% loss in ChAT activity was reported in
brains from patients at these stages of AD.
139 However,
another study using the Clinical Dementia Rating
(CDR) scale suggests that the greatest reduction in
markers of the cholinergic system occurs between mod-
erate (CDR 2.0) and severe (CDR 5.0) disease with lit-
tle change between nondemented and the mild stage
(CDR 0-2).
140
There has been a recent shift of emphasis regarding the
clinical significance of cholinergic deficits.Noncognitive
or neuropsychiatric, in addition to cognitive, symptoms
also appear to have a cholinergic component.
141 For
example, visual hallucinations relate to neocortical
cholinergic deficits,
142 such deficits (eg, loss of ChAT)
being greater in dementia with Lewy bodies (DLB),
where hallucinations are common, than in AD, where
they are less common.
143 Reductions in cortical ChAT
activity in patients with dementia, in addition to corre-
lating with cognitive decline,are also related to overac-
tivity and aggressive behavior.
144
Glutamate. Although neurochemical studies of gluta-
mate neurotransmission have failed to demonstrate
extensive alterations, this may be related to the difficul-
ty in distinguishing the transmitter pool of glutamate
from the metabolic pool. Nevertheless, glutamate con-
centration was reduced by 14% in temporal lobe biopsy
samples and by 86% in the terminal zone of the per-
forant pathway at autopsy of AD patients.
145 Uptake of
D-aspartate, a putative marker of glutamatergic nerve
endings,is also reduced in many cortical areas in the AD
brain.
146 In addition, loss of synapses and pyramidal cell
perikarya (both considered to be markers of gluta-
matergic neurones) from the neocortex of AD patients
correlate with measures of cognitive decline.
71Thus,addi-
tional factors other than impaired cholinergic function
are likely to contribute to cognitive impairment in AD.
However, it is important to remember that glutamater-
gic neurons of the neocortex and hippocampus are influ-
enced by acetylcholine through nicotinic and muscarinic
receptors.
147,148 Thus, treatment of patients with choli-
nomimetics is likely to increase glutamatergic function.
Other neurotransmitters. In biopsy samples from AD
patients, some noradrenergic markers are affected,
Basic research
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are not altered.When postmortem studies of AD brain
are considered many neurotransmitter systems, includ-
ing GABA and somatostatin,are involved or are affect-
ed to a greater extent.
71 Changes in serotonergic neuro-
transmission seen at biopsy,postmortem,and recently in
vivo
68,149 may be linked to the behavioral disturbances of
AD, such as depression, rather than cognitive dysfunc-
tion. For example, patients with AD who were also
depressed had lower numbers of serotonin reuptake
sites in the neocortex than AD patients without this
symptom.
150 Furthermore,both reduced serotonergic
151,152
and increased noradrenergic activities and sensitivi-
ty
153,154 have been linked to aggressive behavior.
Neurotransmitter receptors.The majority of neurotrans-
mitter receptors appear to be unaffected in AD;howev-
er, studies have demonstrated a reduced numbers of
nicotinic and muscarinic (M2) acetylcholine receptors,
some of which are considered to be located on presy-
naptic cholinergic terminals. The M1  subtype is
unchanged, but the coupling of the receptor to its G-
protein may be impaired.
155,156
A highly consistent receptor abnormality in AD is the
loss of the nicotinic receptor,
157-159 which appears to pri-
marily reflect loss of the α 4-containing subtype (gener-
ally associated with α 2), as opposed to α 3 or α 7 sub-
types.
160 Immunohistochemically, loss of α 4 and α 2
reactive fibers has been observed in temporal cortex,
associated with reactive neuropil threads, tangles, and
plaques.
161
Links between neurotransmission 
and neuropathology
There is increasing evidence that various neurotrans-
mitter systems are capable of influencing the metabo-
lism of APP,favoring nonamyloidogenic processing.
162 In
particular, stimulation of muscarinic M1 receptors
increases APP secretion, while decreasing β -amyloid
production.
163 These results suggest that compounds
developed for symptomatic treatment may have a
serendipitous effect on the continuing emergence of
pathology by reducing the production of Aβ .
Cholinergic neurotransmission may be a specific target
for Aβ , since it has been shown to reduce both choline
uptake and acetylcholine release in vitro.
164 Further-
more,Aβ is reported to bind with high affinity to the α 7
subtype of the nicotinic receptor,suggesting that cholin-
ergic function through this receptor may be compro-
mised because of high levels of (soluble) peptide in AD
brains.
165
Translation of discoveries into therapeutics
Biochemical studies in AD have generated a large num-
ber of therapeutic strategies for AD,many of which have
been tested in same-scale, inconclusive studies. Only a
few strategies have gone on to full-scale clinical trials.
The best known of these is related to the cholinergic
deficit. Moreover, while there are a number of rational
approaches, including precursor loading and the use of
muscarinic or nicotinic agonists, the use of acetyl-
cholinesterase inhibitors (AChE-Is) is the most well-
developed approach to the treatment of AD to date (Fig-
ure 3).
166 Tacrine underwent large-scale clinical studies
and clearly established the benefits of AChE-I treatment
in patients with a diagnosis of probable AD.Statistically
significant,dose-related improvements on objective per-
formance-based tests of cognition, clinician- and care-
giver-rated global evaluations of patient well-being,and
also quality of life measures have been reported.
167
Tacrine was subsequently approved for use in some,but
not all, countries.Adverse side effects, including raised
liver enzymes,have limited the use of this compound.
Further AChE-Is have been developed including
donepezil,rivastigmine,metrifonate,and galantamine.
166
Such compounds demonstrate a clinical effect and mag-
nitude of benefit of at least that reported for tacrine,
but with a more favorable clinical profile including
fewer and less serious side effects. Furthermore, evi-
dence is emerging from clinical trials of cholinomimet-
ics that such drugs may improve the abnormal noncog-
nitive, behavioral symptoms of AD.The cholinesterase
inhibitors physostigmine,tacrine,rivastigmine,and met-
rifonate have variously been reported in controlled tri-
als to decrease psychoses (hallucinations and delu-
sions), agitation, apathy, anxiety, disinhibition, pacing
and aberrant motor behavior, and lack of cooperation
in AD.
141,168
Future directions: merging 
technologies
Investigational neuropharmacologic techniques com-
prise a powerful and complementary collection of
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ease on regional and specific measures of brain function.
These have allowed us to characterize both the normal
neurochemical changes that accompany successful aging
and the accelerated or aberrant alterations seen in neu-
ropsychiatric and behavioral dysfunction. Future work
will carry the findings of the past decade into the realm
of intervention.Advancements in structural and func-
tional imaging naturally complement those in molecular
neurobiology and genetics, but we are just beginning to
realize their potential combined power.For example,the
recent availability of animal PET scanners presents the
opportunity for the in vivo study of genetic models of
disease, such as AD. Further, neuropharmacologic
approaches to cognitive enhancement and slowing of
dementia progression may be evaluated and monitored
by imaging strategies.Indeed,the challenges posed by an
increasingly aged population in industrialized nations
are formidable, but may best be met by the combined
application of developing technologies.❑
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A. Proposed neurochemical changes in AD  B. Rectification of neurotransmission 
     with cholinesterase inhibitors
ACh ACh
Glu
AChE
mAChR
nAChR
APP
APP
Cortical pyramidal neuron Cortical pyramidal neuron
KEY
1. Reduced cortical cholinergic innervation
2. Reduced corticortical glutamatergic neurotransmission due 
    to neurone/synapse loss
3. Reduced coupling of muscarinic M1 receptors 
    to second messenger system?
4. Shift of tau to the hyperphosphorylated state - precursor 
    of  neurofibrillary tangles
5. Reduce secretion of sAPPα
6. Increased production of Aβ￿
7. Decreased glutamate production
* It is hypothesized that the above changes give rise to the clinical symptoms 
   of AD and contribute to the spread of pathology
KEY
1. AChE inhibitors reduce the breakdown of 
    endogenously released ACh, resulting in greater 
    activation of postsynaptic ACh receptors
Hypothesized consequences:
2. Reduced phosphorylation of tau
3. Secretion of sAPPα returned towards normal
4. Reduced Aβ production
5. Glutamatergic neurotransmission returns towards normal, 
    possibly due to activation of muscarinic and nicotinic receptors 
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Figure 3. Schematic diagram of a neuron representing (A) alterations in neurotransmission in Alzheimer's disease and (B) the hypothetical mode of
action of acetylcholinesterase inhibitors. ACh, acetylcholine; AChE, acetylcholinesterase; Glu, glutamate; mAChR, ACh muscarinic receptor;
nAChR; ACh nicotinic receptor; sAPPα , the alpha secretory product of amyloid precursor protein; Aβ , β -amyloid protein.
Reproduced from reference 166: Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol
Neurosurg Psychiatry. 1999;66:137-147. Copyright © 1999, Journal of Neurology, Neurosurgery, and Psychiatry.Brain aging research - Meltzer and Francis Dialogues in Clinical Neuroscience - Vol 3 . No.3 . 2001
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La investigación sobre el envejecimiento
cerebral hacia finales del siglo XX: desde la
experimentación a la clínica
El notable y continuo crecimiento en el campo de
la investigación sobre el envejecimiento cerebral
ha sido incentivado por una confluencia de facto-
res. El desarrollo de la biología molecular, de las
técnicas de imágenes y de la genética, en conjun-
to con la exigencia determinada por el envejeci-
miento de la población han creado un terreno fér-
til para mejorar la comprensión acerca de la
interacción entre la función cerebral y la conducta.
Los cambios que produce el envejecimiento en los
sistemas neuroquímicos pueden explicar el espec-
tro de estados cognitivos y conductuales de perso-
nas de edad avanzada que han sido exitosas, pero
también pueden contribuir a incrementar la vul-
nerabilidad a enfermedades depresivas o demen-
cias. En particular, el refinamiento de las técnicas
de imágenes in vivo que permiten investigar la
estructura y función del cerebro que envejece ha
dado la oportunidad de fortalecer nuestro conoci-
miento acerca del sustrato biológico del envejeci-
miento cerebral y de los trastornos neuropsiquiá-
tricos, y traducir este conocimiento en terapias. 
La recherche sur le vieillissement cérébral à
la fin du XXe siècle : de l’expérimentation à
la clinique
Un ensemble de facteurs convergents a contribué
au développement remarquable et constant de la
recherche sur le vieillissement cérébral. C’est ainsi
que les avancées de la biologie moléculaire, de
l’imagerie et de la génétique tout autant que les
impératifs liés au vieillissement inéluctable de la
population ont créé un terrain propice à la
recherche d'une meilleure compréhension de l’in-
teraction entre la fonction cérébrale et le com-
portement. Si les modifications des systèmes neu-
rochimiques dues à l’âge peuvent expliquer
l’éventail des états cognitifs et comportementaux
de patients qui ont bien vieilli, elles peuvent aussi
contribuer à une augmentation de la vulnérabili-
té aux maladies dépressives ou démentielles. Les
perfectionnements des méthodes utilisant l'ima-
gerie in vivo pour analyser la structure et la fonc-
tion du cerveau vieillissant ont permis de consoli-
der nos connaissances sur le substrat biologique
du cerveau vieillissant et les désordres neuropsy-
chiatriques et de traduire celles-ci sous forme de
thérapeutiques.
REFERENCES
1. Jernigan T, Archibald S, Berhow M, Sowell E, Foster D, Hesselink J. Cere-
bral structure on MRI, part I: localization of age-related changes. Biol Psy-
chiatry. 1991;29:55-67.
2. Blatter D, Bigler E, Gale S, et al. Quantitative volumetric analysis of brain
MR: normative database spanning 5 decades of life. Am J Neuroradiol.
1995;16:241-251.
3. Miller AKH, Alston RL, Corsellis JAN. Variation with age in the volumes
of grey and white matter in the cerebral hemispheres of man: measure-
ments with an image analyser. Neuropathol Appl Neurobiol. 1980;6:119-132.
4. Jernigan TL, Press GA, Hesselink JR. Methods for measuring brain mor-
phologic features on magnetic resonance images. Arch Neurol. 1990;47:27-32.
5. Ito M, Hatazawa J, Yamaura H, Matsuzawa T. Age-related brain atrophy
and mental deterioration—a study with computed tomography. Br J Radiol.
1981;54:384-390.
6. Murphy D, DeCarli C, Schapiro M, Rapoport S, Horwitz B. Age-related dif-
ferences in volumes of subcortical nuclei, brain matter, and cerebrospinal
fluid in healthy men as measured with magnetic resonance imaging. Arch
Neurol. 1992;49:839-845.
7. Christiansen P, Larsson H, Thomsen C, Wieslander S, Henriksen O. Age
dependent white matter lesions and brain volume changes in healthy vol-
unteers. Acta Radiol. 1994;35:117-122.
8. Wahlund LO, Agartz I, Almqvist O, et al. The brain in healthy aged indi-
viduals: MR imaging. Radiology. 1990;174:675-679.
9. Golomb J, Kluger A, de Leon MJ, et al. Hippocampal formation size in
normal human aging: a correlate of delayed secondary memory perfor-
mance. Learn Mem. 1994;1:45-54.
10. DeCarli C, Murphy D, Gillette J, et al. Lack of age-related differences in tem-
poral lobe volume of very healthy adults. Am J Neuroradiol. 1994;15:689-696.
11. Resnick S, Davatzikos C, Kraut M, Zonderman A. Longitudinal changes
in MRI volumes in older adults. Presented at First International Meeting of
the Alzheimer's Imaging Consortium 2000. Washington DC. 2000.
12. Autti T, Raininko R, Vanhanen SL, Kallio M, Santavuori P. MRI of the
normal brain from early childhood to middle age. I. Appearances on T2- and
proton density-weighted images and occurrence of incidental high-signal
foci. Neuroradiology. 1994;36:644-648.
13. Horikoshi T, Yagi S, Fukamachi A. Incidental high-intensity foci in white
matter on T2-weighted magnetic resonance imaging. Frequency and clini-
cal significance in symptom-free adults. Neuroradiology. 1993;35:151-155.
14. Longstreth W, Manolio T, Arnold A, et al. Clinical correlates of white
matter findings on cranial magnetic resonance imaging of 3301 elderly
people. The Cardiovascular Health Study. Stroke. 1996;27:1274-1282.
15. Yetkin F, Fischer M, Papke R, Haughton V. Focal hyperintensities in cere-
bral white matter on MR images of asymptomatic volunteers: correlation
with social and medical histories. Am J Roentgenol. 1993;161:855-858.
16. Kalaria R. Cerebrovascular degeneration is related to amyloid-β protein
deposition in Alzheimer's disease. Ann N Y Acad Sci. 1997;826:263-271.
17. Pantoni L, Garcia J. Cognitive impairment and cellular/vascular changes
in cerebral white matter. Ann N Y Acad Sci. 1997;826:92-101.
18. Hatazawa J, Shimosegawa E, Satoh T, Toyoshima H, Okudera T. Subcor-
tical hypoperfusion associated with asymptomatic white matter lesions on
magnetic resonance imaging. Stroke. 1997;28:1944-1947.
19. Kuwabara Y, Ichiya Y, Sasaki M, et al. Cerebral blood flow and vascular
response to hypercapnia in hypertensive patients with leukoaraiosis. Ann
Nucl Med. 1996;10:293-298.Basic research
178
20. Miyazawa N, Satoh T, Hashizume K, Fukamachi A. Xenon contrast CT-
CBF measurements in high-intensity foci on T2-weighted MR images in cen-
trum semiovale of asymptomatic individuals. Stroke. 1997;28:984-987.
21. Yamaji S, Ishii K, Sasaki M, et al. Changes in cerebral blood flow and oxy-
gen metabolism related to magnetic resonance imaging white matter
hyperintensities in Alzheimer's disease. J Nucl Med. 1997;38:1471-1474.
22. Lesser I, Boone K, Mehringer C, Wohl M, Miller B, Berman N. Cognition
and white matter hyperintensities in older depressed patients. Am J Psychi-
atry. 1996;153:1280-1287.
23. Coleman P, Flood D. Neuron numbers and dendritic extent in normal
aging and Alzheimer's disease. Neurobiol Aging. 1987;8:521-545.
24. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Sci-
ence. 1997;278:412-419.
25. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but
exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol.
1997;41:17-24.
26. Geinisman Y, Detoledo-Morrell L, Morrell F, Heller R. Hippocampal
markers of age-related memory dysfunction: behavioral, electrophysiolog-
ical and morphological perspectives. Prog Neurobiol. 1995;45:223-252.
27. Barnes C. Normal aging: regionally specific changes in hippocampal
synaptic transmission. Trends Neurosci. 1994;17:13-18.
28. Davis S, Ackerman R, Correia J, et al. Cerebral blood flow and cere-
brovascular CO2 reactivity in stroke-age normal controls. Neurology.
1983;33:391-399.
29. Shaw T, Mortel K, Meyer J, Rogers R, Hardenberg J, Cutaia M. Cerebral
blood flow changes in benign aging and cerebrovascular disease. Neurolo-
gy. 1984;34:855-862.
30. Melamed E, Lavy S, Bentin S, Cooper G, Rinot Y. Reduction in regional
cerebral blood flow during normal aging in man. Stroke. 1980;11:31-35.
31. Gur R, Gur R, Obrist W, Skolnick B, Reivich M. Age and regional cerebral
blood flow at rest and during cognitive activity. Arch Gen Psychiatry.
1987;44:617-621.
32. Leenders K, Perani D, Lammertsma A, et al. Cerebral blood flow, blood
volume and oxygen utilization. Normal values and effect of age. Brain.
1990;113:27-47.
33. Pantano P, Baron JC, Lebrun-Grandie P, Duquesnoy N, Bousser MG,
Comar D. Regional cerebral blood flow and oxygen consumption in human
aging. Stroke. 1984;15:635-641.
34. Marchal G, Rioux P, Petit-Taboue MC, et al. Regional cerebral oxygen
consumption, blood flow, and blood volume in healthy human aging. Arch
Neurol. 1992;49:1013-1020.
35. Yamaguchi T, Kanno I, Uemura K, et al. Reduction in regional cerebral
metabolic rate of oxygen during human aging. Stroke. 1986;17:1220-1228.
36. Takada H, Nagata K, Hirata Y, et al. Age-related decline of cerebral oxy-
gen metabolism in normal population detected with positron emission
tomography. Neurol Res. 1992;14(suppl):128-131.
37. Kessler RM, Ellis JR, Eden M. Analysis of emission tomographic scan
data: limitations imposed by resolution and background. J Comput Assist
Tomogr. 1984;8:514-522.
38. Meltzer C, Cantwell M, Greer P, et al. Does cerebral blood flow decline
in healthy aging? A PET study with partial volume correction. J Nucl Med.
2000;41:1842-1848.
39. Fazio F, Perani D. Importance of partial-volume correction in brain PET
studies. J Nucl Med. 2000;41:1849-1850.
40. Toyoda K, Fujii K, Takata Y, Ibayashi S, Fujikawa M, Fujishima M. Effect
of aging on regulation of brain stem circulation during hypotension. J Cereb
Blood Flow Metab. 1997;17:680-685.
41. Kuhl D, Metter E, Riege W, Phelps M. Effects of human aging on pat-
terns of local cerebral glucose utilization determined by the [
18F]fluo-
rodeoxyglucose method. J Cereb Blood Flow Metab. 1982;2:163-171.
42. Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur R.
Regional cerebral function determined by FDG-PET in healthy volunteers:
normal patterns and changes with age. J Nucl Med. 1995;36:1141-1149.
43. Salmon E, Maquet P, Sadzot B, Degueldre C, Lemaire C, Franck G.
Decrease of frontal metabolism demonstrated by positron emission tomog-
raphy in a population of healthy elderly volunteers. Acta Neurol Belg.
1991;91:288-295.
44. Duara R, Grady C, Haxby J, et al. Human brain glucose utilization and
cognitive function in relation to age. Ann Neurol. 1984;16:702-713.
45. Rapp P, Amaral D. Individual differences in the cognitive and neurobi-
ological consequences of normal aging. Trends Neurosci. 1992;15:340-345.
46. DeKosky S, Palmer A. Neurochemistry of aging. In: Albert M, Knoefel J, eds.
Clinical Neurology of Aging. 2nd ed. New York, NY: Oxford Press; 1994:79-101.
47. Wong WF, Pearlson GD, Tune LE, et al. Quantification of neuroreceptors
in the living human brain: IV. Effect of aging and elevations of D2-like
receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab.
1997;17:331-342.
48. Wong D, Wagner HJ, Dannals R, et al. Effects of age on dopamine and
serotonin receptors measured by positron tomography in the living human
brain. Science. 1984;226:1393-1396.
49. Meltzer C, Smith G, Reynolds C, et al. Reduced binding of [
18F]altanserin
to serotonin type 2A receptors in aging: persistence of effect after partial
volume correction. Brain Res. 1998;813:167-171.
50. Rosier A, Dupont P, Peuskens J, et al. Visualisation of loss of 5-HT2A
receptors with age in healthy volunteers using [
18F] and positron emission
tomographic imaging. Psychiatr Res. 1996;68:11-22.
51. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human
brain mu-opioid receptor binding measured by PET. Am J Psychiatry.
1999;156:842-848.
52. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's
disease. J Neural Transm. 1993;91:135-159.
53. Allen S, Benton J, Goodhardt M, et al. Biochemical evidence of selective
nerve cell changes in the normal ageing human and rat brain. J Neurochem.
1983;41:256-265.
54. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes
in the human brain: changes with aging and dementia. J Neurosci Res.
1992;31:103-111.
55. Cohen B, Renshaw P, Stoll A, Wurtman R, Yurgelun-Todd D, Babb S.
Decreased brain choline uptake in older adults. An in vivo proton magnet-
ic spectroscopy study. JAMA. 1995;274:902-907.
56. Dewey S, Volkow N, Logan J, et al. Age-related decreases in muscarinic
cholinergic receptor binding in the human brain measured with positron
emission tomography (PET). J Neurosci Res. 1990;27:569-575.
57. Lee KS, Frey KA, Koeppe RA, Buck A, Mulholland GK, Kuhl DE. In vivo
quantification of cerebral muscarinic receptors in normal human aging
using positron emission tomography and [
11C]tropanyl benzilate. J Cereb
Blood Flow Metab. 1996;16:303-310.
58. Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y. Age-related
changes in human muscarinic acetylcholine receptors measured by positron
emission tomography. Neurosci Lett. 1993;149:225-228.
59. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic
terminals in normal aging, Alzheimer's disease, and Parkinson's disease.
Ann Neurol. 1996;40:399-410.
60. Wang Y, Chan GL, Holden JE, et al. Age-dependent decline of dopamine
D1 receptors in human brain: a PET study. Synapse. 1998;30:56-61.
61. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in
brain dopamine activity with age and cognitive and motor impairment in
healthy individuals. Am J Psychiatry. 1998;155:344-349.
62. Volkow ND, Wang GJ, Fowler JS, et al. Parallel loss of presynaptic and post-
synaptic dopamine markers in normal aging. Ann Neurol. 1998;44:143-147.
63. Volkow ND, Ding YS, Fowler JS, et al. Dopamine transporters decrease
with age. J Nucl Med. 1996;37:554-559.
64. Rinne JO, Sahlberg N, Ruottinen H, Nagren K, Lehikoinen P. Striatal
uptake of the dopamine reuptake ligand [
11C]beta-CFT is reduced in
Alzheimer's disease assessed by positron emission tomography. Neurology.
1998;50:152-156.
65. Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging
with fluorine-18 FPCIT and PET. J Nucl Med. 1998;39:1521-1530.
66. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychia-
try. 1998;44:151-162.
67. Crouzel C, Guillaume M, Barre L, Lemaire C, Pike VW. Ligands and trac-
ers for PET studies of the 5-HT system—current status. Int J Rad Appl Instrum
B. 1992;19:857-870.
68. Blin J, Baron JC, Dubois B, et al. Loss of brain 5HT2 receptors in
Alzheimer's disease. Brain. 1993;116:497-510.
69. Meltzer CC, Drevets WC, Price JC, et al. Gender-specific aging effects on
the serotonin 1A receptor. Brain Res. 2001;895:9-17.
70. Palmer A, DeKosky S. Neurochemistry. In: Pathy M, ed. Principles and Prac-
tice of Geriatric Medicine. Chichester, UK: John Wiley & Sons; 1998:65-76.Brain aging research - Meltzer and Francis Dialogues in Clinical Neuroscience - Vol 3 . No.3 . 2001
179
71. Francis P, Sims N, Procter A, Bowen D. Cortical pyramidal neurone loss
may cause glutamatergic hypoactivity and cognitive impairment in
Alzheimer's disease: investigative and therapeutic perspectives. J Neu-
rochem. 1993;60:1589-1604.
72. Mouradian M, Contreras P, Monahan J, Chase T. [
3H]MK-801 binding in
Alzheimer's disease. Neurosci Lett. 1988;93:225-230.
73. Procter A, Stirling J, Stratmann G, Cross A, Bowen D. Loss of glycine-
dependent radioligand binding to the N-methyl-D-aspartate-phencyclidine
receptor complex in patients with Alzheimer's disease. Neurosci Lett.
1989;101:62-66.
74. Piggott M, Perry E, Perry R, Court J. [
3H]MK-801 binding to the NMDA
receptor complex, and its modulation in human frontal cortex during devel-
opment and aging. Brain Res. 1992;588:277-286.
75. Magnusson KR. Declines in mRNA expression of different subunits may
account for differential effects of aging on agonist and antagonist binding
to the NMDA receptor. J Neurosci. 2000;20:1666-1674.
76. Hutchison JB, Wozniak A, Beyer C, Karolczak M, Hutchison RE. Steroid
metabolising enzymes in the determination of brain gender. J Steroid
Biochem Mol Biol. 1999;69:85-96.
77. Schmidt PJ, Rubinow DR. Neuroregulatory role of gonadal steroids in
humans. Psychopharmacol Bull. 1997;33:219-220.
78. Honeycutt N, Li Q, Yates K, et al. Gender differences in hippocampal,
amygdaloid and frontal volumes across the lifespan: a cross-sectional study.
Biol Psychiatry. 2000;47:98S.
79. Cathcart C, Jones SE, Pumroy C, Peters G, Knox SM, Cheek JH. Clinical
recognition and management of depression in node negative breast cancer
patients treated with tamoxifen. Breast Cancer Res Treat. 1993;27:277-281.
80. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment
of depression in late life. Consensus statement update. JAMA.
1997;278:1186-1190.
81. Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on
the prevalence of depressive conditions: report from the National Survey
of Psychiatric Morbidity. Psychol Med. 1998;28:9-19.
82. Eaton WW, Anthony JC, Gallo J, et al. Natural history of Diagnostic
Interview Schedule/DSM-IV major depression. The Baltimore Epidemiolog-
ic Catchment Area follow-up. Arch Gen Psychiatry. 1997;54:993-999.
83. Luine VN, Richards ST, Wu VY, Beck KD. Estradiol enhances learning and
memory in a spatial memory task and effects levels of monoaminergic neu-
rotransmitters. Horm Behav. 1998;34:149-162.
84. O'Neal MF, Means LW, Poole MC, Hamm RJ. Estrogen affects perfor-
mance of ovariectomized rats in a two-choice water-escape working mem-
ory task. Psychoneuroendocrinology. 1996;21:51-65.
85. Hampson E, Kimura D. Reciprocal effects of hormonal fluctuations on
human motor and perceptual-spatial skills. Behav Neurosci. 1988;102:456-459.
86. Hampson E. Variations in sex-related cognitive abilities across the men-
strual cycle. Brain Cogn. 1990;14:26-43.
87. Hampson E. Estrogen-related variations in human spatial and articula-
tory-motor skills. Psychoneuroendocrinology. 1990;15:97-111.
88. Phillips SM, Sherwin BB. Variations in memory function and sex steroid hor-
mones across the menstrual cycle. Psychoneuroendocrinology. 1992;17:497-506.
89. Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondement-
ed older women who took estrogen after menopause. Neurology.
1998;50:368-373.
90. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and
cognitive function in older women. JAMA. 1993;269:2637-2641.
91. Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS. Depressive
symptoms and cognitive decline in nondemented elderly women: a
prospective study. Arch Gen Psychiatry. 1999;56:425-430.
92. Barrett-Connor E, Goodman-Gruen D. Cognitive function and endoge-
nous sex hormones in older women. J Am Geriatr Soc. 1999;47:1289-1293.
93. Yaffe K, Grady D, Pressman A, Cummings S. Serum estrogen levels, cog-
nitive performance, and risk of cognitive decline in older community
women. J Am Geriatr Soc. 1998;46:816-21.
94. Barrett-Connor E, Kritz-Silverstein D. Gender differences in cognitive
function with age: the Rancho Bernardo study. J Am Geriatr Soc.
1999;47:159-164.
95. Gooren LI. The age-related decline of androgen levels in men: clinical-
ly significant? Br J Urol. 1996;78:763-768.
96. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychia-
try. 1996;153:974-984.
97. Kerr JE, Allore RJ, Beck SG, Handa RJ. Distribution and hormonal regu-
lation of androgen receptor (AR) and AR messenger ribonucleic acid in the
rat hippocampus. Endocrinology. 1995;136:3213-3221.
98. Pouliot WA, Handa RJ, Beck SG. Androgen modulates N-methyl-D-aspar-
tate-mediated depolarization in CA1 hippocampal pyramidal cells. Synapse.
1996;23:10-19.
99. Christiansen K, Knussmann R. Sex hormones and cognitive functioning
in men. Neuropsychobiology. 1987;18:27-36.
100. Moffat S, Hampson E. A curvilinear relationship between testosterone
and spatial cognition in humans: possible influence of hand preference. Psy-
choneuroendocrinology. 1996;21:323-337.
101. Janosky J, Oviatt S, Orwoll E. Testosterone influences spatial cognition
in older men. Behav Neurosci. 1994;108:325-332.
102. Maas D, Jochen A, Lalande B. Age-related changes in male gonadal
function. Implications for therapy. Drugs Aging. 1997;11:45-60.
103. Baldwin RC, Tomenson B. Depression in later life. A comparison of
symptoms and risk factors in early and late onset cases. Br J Psychiatry.
1995;167:649-652.
104. Figiel G, Krishnan K, Doraiswamy P, Rao V, Nemeroff C, Boyko O. Sub-
cortical hyperintensities on brain magnetic resonance imaging: a compari-
son between late age onset and early onset elderly depressed subjects. Neu-
robiol Aging. 1991;12:245-247.
105. Alexopoulos G, Young R, Shindledecker R. Brain computed tomogra-
phy findings in geriatric depression and primary degenerative dementia.
Biol Psychiatry. 1992;31:591-599.
106. Iidaka T, Nakajima T, Kawamoto K, et al. Signal hyperintensities on
brain magnetic resonance imaging in elderly depressed patients. Eur Neu-
rol. 1996;36:293-299.
107. Krishnan K, Hays J, Blazer D. MRI-defined vascular depression. Am J Psy-
chiatry. 1997;154:497-501.
108. Lesser I, Hill-Gutierrez E, Miller B, Boone K. Late-onset depression with
white matter lesions. Psychosomatics. 1993;34:364-367.
109. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silberswieg D,
Charlson M. "Vascular depression” hypothesis. Arch Gen Psychiatry.
1997;54:915-922.
110. McBean DE, Sharkey J, Ritchie IM, Kelly PA. Evidence for a possible role
for serotonergic systems in the control of cerebral blood flow. Brain Res.
1990;537:307-310.
111. McBean DE, Sharkey J, Ritchie IM, Kelly PA. Cerebrovascular and functional
consequences of 5-HT1A receptor activation. Brain Res. 1991;555:159-163.
112. Hajdu MA, McElmurry RT, Heistad DD, Baumbach GL. Effects of aging
on cerebral vascular responses to serotonin in rats. Am J Physiol. 1993;264(6
Pt 2):H2136-H2140.
113. Arango V, Ernsberger P, Marzuk P, et al. Autoradiographic demon-
stration of increased serotonin 5-HT2 and β -adrenergic receptor binding
sites in the brain of suicide victims. Arch Gen Psychiatry. 1990;47:1038-1047.
114. Stanley M, Mann J. Increased serotonin-2 binding sites in the frontal
cortex of suicide victims. Lancet. 1983;i:214-216.
115. Arango V, Underwood M, Gubbi A, Mann J. Localized alterations in
pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal
cortex of suicide victims. Brain Res. 1995;688:121-133.
116. Stockmeier C, Dilley G, Shapiro L, Overholser J, Thompson P, Meltzer
H. Serotonin receptors in suicide victims with major depression. Neuropsy-
chopharmacology. 1996;16:162-173.
117. Stockmeier C, Dilley G, Shapiro L, Kolli T, Thompson P, Rajkowska G.
Increase in serotonin-1A autoreceptors in the midbrain of suicide victims
with major depression—postmortem evidence for decreased serotonin
activity? Soc Neurosci Abstr. 1997;23:1676.
118. Austin M, Whitehead R, Edgar C, Lewis D. Decreased serotonin trans-
porter-immunoreactive axons in the prefrontal cortex of suicide victims
with major depression. Soc Neurosci Abstr. 1999;25:2098.
119. Arango V, Underwood M, Bakalian M, et al. Reduction in serotonin
transporter sites in prefrontal cortex is localized in suicide and widespread
in major depression. Soc Neurosci Abstr. 1999;25:1798.
120. Bowen DM, Najlerahim A, Procter A, Francis P, Murphy E. Circum-
scribed changes of the cerebral cortex in neuropsychiatric disorders of late
life. Proc Natl Acad Sci U S A. 1989;86:9504-9508.
121. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in
depression: a potential predictor of treatment response. Neuroreport.
1997;8:1057-1061.Basic research
180
122. Drevets W, Price J, Simpson J, et al. Subgenual prefrontal cortex abnor-
malities in mood disorders. Nature. 1997;386:824-770.
123. Bench C, Friston K, Brown R, Scott L, Frackowiak R, Dolan R. The
anatomy of melancholia—focal abnormalities of cerebral blood flow in
major depression. Psychol Med. 1992;22:607-615.
124. Mann J, McBride P, Malone K, DeMeo M, Keilp J. Blunted serotonergic
responsivity in depressed patients. Neuropsychopharmacology. 1995;13:53-64.
125. Mann J, Malone K, Diehl D, Perel J, Cooper T, Mintun M. Demonstra-
tion in vivo of reduced serotonin responsivity in the brain of untreated
depressed patients. Am J Psychiatry. 1996;153:174-182.
126. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Sero-
tonin 5-HT2 receptor imaging in major depression: focal changes in orbito-
insular cortex. Br J Psychiatry. 1997;171:444-448.
127. Meltzer C, Price J, Mathis C, et al. PET imaging of serotonin type 2A
receptors in late-life neuropsychiatric disorders. Am J Psychiatry.
1999;156:1871-1878.
128. Drevets W, Frank E, Price J, et al. PET imaging of serotonin 1A recep-
tor binding in depression. Biol Psychiatry. 1999;46:1375-1387.
129. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's dis-
ease revisited. Am J Publ Health. 1994;84:1261-1264.
130. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in
the United States and the public health impact of delaying disease onset.
Am J Publ Health. 1998;88:1337-1342.
131. Braak H, Braak E. Neuropathological staging of Alzheimer-related
changes. Acta Neuropathol (Berl). 1991;82:239-259.
132. Francis PT, Pangalos MN, Stephens PH, et al. Antemortem measurements
of neurotransmission: possible implications for pharmacotherapy of
Alzheimer's disease and depression. J Neurol Neurosurg Psychiatry. 1993;56:80-84.
133. Pericak-Vance MA, Bebout JL, Gaskell PC Jr, et al. Linkage studies in
familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum
Genet. 1991;48:1034-1050.
134. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's
disease increase production of 42-residue amyloid beta-protein in both
transfected cells and transgenic mice. Nat Med. 1997;3:67-72.
135. Bowen D, Smith C, White P, Davison A. Neurotransmitter-related
enzymes and indices of hypoxia in senile dementia and other abiotrophies.
Brain. 1976;99:459-496.
136. Davies P, Maloney A. Selective loss of central cholinergic neurons in
Alzheimer's disease. Lancet. 1976;2:1403.
137. Perry E, Gibson P, Blessed G, Perry R, Tomlinson B. Neurotransmitter
abnormalities in senile dementia. J Neurol Sci. 1977;34:247-265.
138. Bartus R, Dean R, Beer B, Lippa A. The cholinergic hypothesis of geri-
atric memory dysfunction. Science. 1982;217:408-417.
139. Beach T, Kuo Y, Spiegel K, et al. The cholinergic deficit coincides with
Abeta deposition at the earliest histopathologic stages of Alzheimer dis-
ease. J Neuropathol Exp Neurol. 2000;59:308-313.
140. Davis P, Mohs R, Marin D, et al. Cholinergic markers in elderly patients
with early signs of Alzheimer disease. JAMA. 1999;281:1401-1406.
141. Cummings J, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease:
the cholinergic hypothesis revisited. Neurology. 1996;47:876-883.
142. Perry E, Marshall E, Thompson P, et al. Monoaminergic activities in
Lewy-body-dementia—relation to hallucinosis and extrapyramidal features.
J Neural Transm. 1993;6:167-177.
143. Perry E, Haroutunian V, Davis K, et al. Neocortical cholinergic activities
differentiate Lewy body dementia from classical Alzheimer's disease. Neu-
roreport. 1994;5:747-749.
144. Minger S, Esiri M, McDonald B, et al. Cholinergic deficits contribute to
behavioural disturbance in patients with dementia. Neurology.
2000;55:1460-1467.
145. Hyman B, Van Hoesen G, Damasio A. Alzheimer's disease: glutamate
depletion in the hippocampal perforant pathway zone. Ann Neurol.
1987;22:37-40.
146. Procter A, Palmer A, Francis P, et al. Evidence of glutamatergic dener-
vation and possible abnormal metabolism in Alzheimer's disease. J Neu-
rochem. 1988;50:790-802.
147. Dijk S, Francis P, Stratmann G, Bowen D. Cholinomimetics increase glu-
tamate outflow by an action on the corticostriatal pathway: implications
for Alzheimer's disease. J Neurochem. 1995;65:2165-2169.
148. Chessell I, Humphrey P. Nicotinic and muscarinic receptor-evoked depo-
larisations recorded from a novel cortical brain slice preparation. Neu-
ropharmacology. 1995;34:1289-1296.
149. Meltzer C, Smith G, DeKosky S, et al. Serotonin in aging, late life
depression, and Alzheimer's disease: the emerging role of functional imag-
ing. Neuropsychopharmacology. 1998;18:407-430.
150. Chen CH, Alder J, Bowen D, et al. Presynaptic serotonergic markers in
community-acquired cases of Alzheimer's disease: correlations with depres-
sion and neuroleptic medication. J Neurochem. 1996;66:1592-1598.
151. Coccaro E. Central serotonin and impulsive aggression. Br J Psychiatry.
1989;155(suppl 8):52-62.
152. Proctor AW, Francis PT, Stratmann GC, Bowen DM. Serotonergic
pathology is not widespread in Alzheimer patients without prominent
aggressive symptoms. Neurochem Res. 1992;17:917-922.
153. Peskind E, Wingerson D, Murray S, et al. Effects of Alzheimer's disease
and normal aging on cerebrospinal fluid norepinephrine responses to
yohimbine and clonidine. Arch Gen Psychiatry. 1995;52:774-782.
154. Raskind M. Evaluation and management of aggressive behavior in the
elderly demented patient. J Clin Psychiatry. 1999;60:45-49.
155. Flynn D, Weinstein D, Mash D. Loss of high-affinity agonist binding to
M1 muscarinic receptors in Alzheimer's disease: implications for the failure
of cholinergic replacement therapies. Ann Neurol. 1991;29:256-262.
156. Jope R, Song L, Powers R. Agonist-induced, GTP-dependent phospho-
inositide hydrolysis in postmortem human brain membranes. J Neurochem.
1994;62:1-7.
157. Aubert I, Araujo D, Cecyre D, Robitaille Y, Gauthier S, Quirion R. Com-
parative alterations of nicotinic and muscarinic binding sites in Alzheimer's
and Parkinson's diseases. J Neurochem. 1992;58:529-541.
158. Court J, Perry E. CNS nicotinic receptors—possible therapeutic targets
in neurodegenerative disorders. CNS Drugs. 1994;2:216-233.
159. Perry E, Morris C, Court J, et al. Alteration in nicotine binding sites in
Parkinson's disease, Lewy body dementia and Alzheimer's: possible index
of early neuropathology. Neuroscience. 1995;64:385-395.
160. MartinRuiz C, Court J, Molnar E, et al. Alpha 4 but not alpha 3 and
alpha 7 nicotinic acetylcholine receptor subunits are lost from the tempo-
ral cortex in Alzheimer' s disease. J Neurochem. 1999;73:1635-1640.
161. Sparks D, Beach T, Lukas R. Immunohistochemical localization of nico-
tinic-2 and -4 receptor subunits in normal human brain and individuals with
Lewy body and Alzheimer's disease: preliminary observations. Neurosci Lett.
1998;256:151-154.
162. Nitsch R. From acetylcholine to amyloid: neurotransmitters and the
pathology of Alzheimer's disease. Neurodegeneration. 1996;5:477-482.
163. Nitsch R, Slack B, Wurtman R, Growdon J. Release of Alzheimer amy-
loid precursor stimulated by activation of muscarinic acetylcholine recep-
tors. Science. 1992;258:304-307.
164. Auld D, Kar S, Quirion R. Beta-amyloid peptides as direct cholinergic
neuromodulators: a missing link? Trends Neurosci. 1998;21:43-49.
165. Wang H, Lee D, Dandrea M, Peterson P, Shank R, Reitz A. Beta-amy-
loid(1-42) binds to alpha 7 nicotinic acetylcholine receptor with high affin-
ity—implications for Alzheimer's disease pathology. J Biol Chem.
2000;275:5626-5632.
166. Francis P, Palmer A, Snape M, Wilcock G. The cholinergic hypothesis of
Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry.
1999;66:137-147.
167. Davis K, Thal L, Gamzu E, et al. A double-blind, placebo-controlled
multicenter study of tacrine for Alzheimer's disease. N Engl J Med.
1992;327:1253-1259.
168. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neuro-
transmitter correlate of consciousness? Trends Neurosci. 1999;22:273-280.